Kim Beckham, an insurance agent in Victoria, Texas, had seen friends suffer so badly from shingles that she wanted to receive the first approved shingles vaccine as soon as it became available, even if she had to pay for it out-of-pocket.<\/p>\n
Her doctor and several pharmacies turned her down because she was below the recommended age at the time, which was 60. So, in 2016, she celebrated her 60th birthday at her local CVS.<\/p>\n
\u201cI was there when they opened,\u201d Beckham recalled. After getting her Zostavax shot, she said, \u201cI felt really relieved.\u201d She has since received the newer, more effective shingles vaccine, as well as a pneumonia shot, an RSV vaccine to guard against respiratory syncytial virus, annual flu shots and all recommended covid-19 vaccinations.<\/p>\n
Some older people are really eager to be vaccinated.<\/p>\n
Robin Wolaner, 71, a retired publisher in Sausalito, California, has been known to badger friends who delay getting recommended shots, sending them relevant medical studies. \u201cI\u2019m sort of hectoring,\u201d she acknowledged.<\/p>\n
Deana Hendrickson, 66, who provides daily care for three young grandsons in Los Angeles, sought an additional MMR shot, though she was vaccinated against measles, mumps, and rubella as a child, in case her immunity to measles had waned.<\/p>\n
For older adults who express more confidence in vaccine safety than younger groups, the past few months have brought welcome research. Studies have found important benefits from a newer vaccine and enhanced versions of older ones, and one vaccine may confer a major bonus that nobody foresaw.<\/p>\n
The new studies are coming at a fraught political moment. The nation\u2019s health secretary, Robert F. Kennedy Jr., has long disparaged certain vaccines, calling them unsafe and saying that the government officials who regulate them are compromised and corrupt.<\/p>\n
On June 9, Kennedy fired a panel of scientific advisers to the Centers for Disease Control and Prevention, and later replaced them with some who have been skeptical of vaccines. But so far, Kennedy has not tried to curb access to the shots for older Americans.<\/p>\n
The evidence that vaccines are beneficial remains overwhelming.<\/p>\n
The phrase \u201cVaccines are not just for kids anymore<\/a>\u201d has become a favorite for William Schaffner, an infectious diseases specialist at Vanderbilt University Medical Center.<\/p>\n \u201cThe population over 65, which often suffers the worst impact of respiratory viruses and others, now has the benefit of vaccines that can prevent much of that serious illness,\u201d he said.<\/p>\n Take influenza, which annually sends from 140,000 to 710,000 people to hospitals, most of them seniors, and is fatal to 10% of hospitalized older adults.\u00a0<\/p>\n For about 15 years, the CDC has approved several enhanced flu vaccines for people 65 and older. More effective than the standard formulation, they either contain higher levels of the antigen that builds protection against the virus or incorporate an adjuvant that creates a stronger immune response. Or they\u2019re recombinant vaccines, developed through a different method, with higher antigen levels.<\/p>\n In a meta-analysis in the Journal of the American Geriatrics Society, \u201call the enhanced vaccine products were superior to the standard dose for preventing hospitalizations,\u201d said Rebecca Morgan, a health research methodologist at Case Western Reserve University and an author of the study.<\/p>\n Compared with the standard flu shot, the enhanced vaccines reduced the risk of hospitalization<\/a> from the flu in older adults, by at least 11% and up to 18%. The CDC advises adults 65 and older to receive the enhanced vaccines<\/a>, as many already do.<\/p>\n More good news: Vaccines to prevent respiratory syncytial virus in people 60 and older are performing admirably.<\/p>\n RSV is the most common cause of hospitalization for infants, and it also poses significant risks to older people. \u201cSeason in and season out,\u201d Schaffner said, \u201cit produces outbreaks of serious respiratory illness that rivals influenza.\u201d<\/p>\n Because the FDA first approved an RSV vaccine in 2023, the 2023-24 season provided \u201cthe first opportunity to see it in a real-world context,\u201d said Pauline Terebuh, an epidemiologist at Case Western Reserve School of Medicine and an author of a recent study<\/a> in the journal JAMA Network Open.<\/p>\n In analyzing electronic health records for almost 800,000 patients, the researchers found the vaccines to be 75% effective against acute infection, meaning illness that was serious enough to send a patient to a health care provider.<\/p>\n The vaccines were 75% effective in preventing emergency room or urgent care visits, and 75% effective against hospitalization, both among those ages 60 to 74 and those older.<\/p>\n Immunocompromised patients, despite having a somewhat lower level of protection from the vaccine, will also benefit from it, Terebuh said. As for adverse effects, the study found a very low risk for Guillain-Barr\u00e9 syndrome, a rare condition that causes muscle weakness and that typically follows an infection, in about 11 cases per 1 million doses of vaccine. That, she said, \u201cshouldn\u2019t dissuade people.\u201d<\/p>\n The CDC now recommends RSV vaccination for people 75 and older, and for those 60 to 74 if they\u2019re at higher risk of severe illness (from, say, heart disease).<\/p>\n As data from the 2024-25 season becomes available, researchers hope to determine whether the vaccine will remain a one-and-done, or whether immunity will require repeated vaccination.<\/p>\n People 65 and up express the greatest confidence in vaccine safety of any adult group, a KFF survey found in April. More than 80% said they were \u201cvery \u201cor \u201csomewhat confident\u201d about MMR, shingles, pneumonia, and flu shots.<\/p>\n Although the covid vaccine drew lower support among all adults, more than two-thirds of older adults expressed confidence in its safety.<\/p>\n Even skeptics might become excited about one possible benefit of the shingles vaccine: This spring, Stanford researchers reported that over seven years, vaccination against shingles reduced the risk of dementia by 20%<\/a>, a finding that made headlines.<\/p>\n Biases often undermine observational studies that compare vaccinated with unvaccinated groups. \u201cPeople who are healthier and more health-motivated are the ones who get vaccinated,\u201d said Pascal Geldsetzer, an epidemiologist at the Knight Initiative for Brain Resilience at Stanford and lead author of the study.<\/p>\n \u201cIt\u2019s hard to know whether this is cause and effect,\u201d he said, \u201cor whether they\u2019re less likely to develop dementia anyway.\u201d<\/p>\n So the Stanford team took advantage of a \u201cnatural experiment\u201d when the first shingles vaccine, Zostavax, was introduced in Wales. Health officials set a strict age cutoff: People who turned 80 on or before Sept. 1, 2013, weren\u2019t eligible for vaccination, but those even slightly younger were eligible.<\/p>\n In the sample of nearly 300,000 adults whose birthdays fell close to either side of that date, almost half of the eligible group received the vaccine, but virtually nobody in the older group did.<\/p>\n \u201cJust as in a randomized trial, these comparison groups should be similar in every way,\u201d Geldsetzer explained. A substantial reduction in dementia diagnoses in the vaccine-eligible group, with a much stronger protective effect in women, therefore constitutes \u201cmore powerful and convincing evidence,\u201d he said.<\/p>\n The team also found reduced rates of dementia after shingles vaccines were introduced in Australia<\/a> and other countries. \u201cWe keep seeing this in one dataset after another,\u201d Geldsetzer said.<\/p>\n In the United States, where a more potent vaccine, Shingrix, became available in 2017 and supplanted Zostavax, Oxford investigators found an even stronger effect<\/a>.<\/p>\n By matching almost 104,000 older Americans who received a first dose of the new vaccine (full immunization requires two) with a group that had received the earlier formulation, they found delayed onset of dementia in the Shingrix group.<\/p>\n How a shingles vaccine might reduce dementia remains unexplained. Scientists have suggested that viruses themselves may contribute to dementia, so suppressing them could protect the brain. Perhaps the vaccine revs up the immune system in general or affects inflammation.<\/p>\n \u201cI don\u2019t think anybody knows,\u201d said Paul Harrison, a psychiatrist at Oxford and a senior author of the study. But, he added, \u201cI\u2019m now convinced there\u2019s something real here.\u201d<\/p>\n Shingrix, now recommended for adults over 50, is 90% effective<\/a> in preventing shingles and the lingering nerve pain that can result. In 2021, however, only 41% of adults 60 and older<\/a> had received one dose of either shingles vaccine.<\/p>\n A connection to dementia will require further research, and Geldsetzer is trying to raise philanthropic funding for a clinical trial.<\/p>\n And \u201cif you needed another reason to get this vaccine,\u201d Schaffner said, \u201chere it is.\u201d<\/p>\n KFF Health News<\/a> is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF\u2014an independent source of health policy research, polling, and journalism. Learn more about KFF<\/a>.<\/p>\nUSE OUR CONTENT<\/h3>\n